[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100310953":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":39,"centralContacts":40,"locations":46,"responsibleParty":448,"collaborators":39,"id":450,"slug":451,"hasResults":452,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":39,"eligibilityCriteria":456,"healthyVolunteers":452,"sex":457,"minAge":458,"maxAge":39,"enrollmentInfo":459,"targetDuration":39,"studyType":462,"phases":463,"briefSummary":466,"conditions":467,"keywords":472,"overallStatus":49,"whyStopped":39,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":498},{"fullName":5,"class":6},"Curis, Inc.","INDUSTRY",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Emavusertib (CA-4948) dose escalation","EXPERIMENTAL","Part A1: Dose-level cohorts with up to approximately 6 participants each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib.",[13],"Drug: Emavusertib",{"label":15,"type":10,"description":16,"interventionNames":17},"Emavusertib (CA-4948) and ibrutinib dose escalation","Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg QD or 420 mg QD of oral ibrutinib. The starting dose of emavusertib to be used in combination will be 200 mg BID. It is anticipated that 12 to 20 participants at a potential dose level will be required to establish optimal combination dosing.",[13,18],"Drug: Ibrutinib",{"label":20,"type":10,"description":21,"interventionNames":22},"Emavusertib (CA-4948) and ibrutinib dose expansion","In two Expansion Cohorts (Part B), emavusertib in combination with ibrutinib will be administered in participants with R\u002FR PCNSL who have progressed on a BTKi. In Cohort 1, emavusertib 100 mg BID will be administered with ibrutinib 560 mg QD consecutively in 28-day treatment cycles. In Cohort 2, emavusertib 200 mg BID will be administered with ibrutinib 560 mg QD consecutively in 28-day treatment cycles.",[13,18],{"label":24,"type":10,"description":25,"interventionNames":26},"Emavusertib (CA-4948) and ibrutinib","In this part of the study (Part C), eligible second-line participants with R\u002FR PCNSL who are naïve to BTKi treatment will receive 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD. Treatments will be administered continuously in 28-day treatment cycles.",[13,18],[28,35],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Emavusertib","Emavusertib will be provided as a tablet dosage form to be taken BID.",[24,15,20,9],[34],"CA-4948",{"type":29,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Ibrutinib","Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.",[24,15,20],null,[41],{"name":42,"role":43,"phone":44,"phoneExt":39,"email":45},"Ahmed Hamdy, MD","CONTACT","617-503-6500","clinicaltrials@curis.com",[47,61,68,78,87,93,103,112,122,132,141,151,161,171,179,185,191,201,211,221,231,240,250,261,270,280,290,296,305,315,323,331,336,346,354,362,372,380,388,396,406,414,422,432,440],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":39},"St. Joseph's Hospital and Medical Center","RECRUITING","Phoenix","Arizona","85013","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-112.07404,33.44838,{"lat":59,"lon":58},{"facility":62,"status":63,"city":50,"state":51,"zip":64,"country":53,"countryCode":54,"cosmosGeoPoint":65,"geoPoint":67,"contacts":39},"Mayo Clinic","COMPLETED","85054",{"type":56,"coordinates":66},[58,59],{"lat":59,"lon":58},{"facility":69,"status":49,"city":70,"state":71,"zip":72,"country":53,"countryCode":54,"cosmosGeoPoint":73,"geoPoint":77,"contacts":39},"City of Hope","Duarte","California","91010",{"type":56,"coordinates":74},[75,76],-117.97729,34.13945,{"lat":76,"lon":75},{"facility":79,"status":49,"city":80,"state":71,"zip":81,"country":53,"countryCode":54,"cosmosGeoPoint":82,"geoPoint":86,"contacts":39},"Providence St. John's Health Center","Santa Monica","90404",{"type":56,"coordinates":83},[84,85],-118.49138,34.01949,{"lat":85,"lon":84},{"facility":88,"status":89,"city":80,"state":71,"zip":81,"country":53,"countryCode":54,"cosmosGeoPoint":90,"geoPoint":92,"contacts":39},"UCLA Department of Medicine - Hematology\u002FOncology","WITHDRAWN",{"type":56,"coordinates":91},[84,85],{"lat":85,"lon":84},{"facility":94,"status":63,"city":95,"state":96,"zip":97,"country":53,"countryCode":54,"cosmosGeoPoint":98,"geoPoint":102,"contacts":39},"Smilow Cancer Hospital at Yale-New Haven","New Haven","Connecticut","06510",{"type":56,"coordinates":99},[100,101],-72.92816,41.30815,{"lat":101,"lon":100},{"facility":62,"status":49,"city":104,"state":105,"zip":106,"country":53,"countryCode":54,"cosmosGeoPoint":107,"geoPoint":111,"contacts":39},"Jacksonville","Florida","32224",{"type":56,"coordinates":108},[109,110],-81.65565,30.33218,{"lat":110,"lon":109},{"facility":113,"status":49,"city":114,"state":115,"zip":116,"country":53,"countryCode":54,"cosmosGeoPoint":117,"geoPoint":121,"contacts":39},"Northwestern Memorial Hospital","Chicago","Illinois","60611",{"type":56,"coordinates":118},[119,120],-87.65005,41.85003,{"lat":120,"lon":119},{"facility":123,"status":49,"city":124,"state":125,"zip":126,"country":53,"countryCode":54,"cosmosGeoPoint":127,"geoPoint":131,"contacts":39},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":56,"coordinates":128},[129,130],-71.05977,42.35843,{"lat":130,"lon":129},{"facility":62,"status":49,"city":133,"state":134,"zip":135,"country":53,"countryCode":54,"cosmosGeoPoint":136,"geoPoint":140,"contacts":39},"Rochester","Minnesota","55905",{"type":56,"coordinates":137},[138,139],-92.4699,44.02163,{"lat":139,"lon":138},{"facility":142,"status":49,"city":143,"state":144,"zip":145,"country":53,"countryCode":54,"cosmosGeoPoint":146,"geoPoint":150,"contacts":39},"Fred and Pamela Buffett Cancer Center","Omaha","Nebraska","68198",{"type":56,"coordinates":147},[148,149],-95.94043,41.25626,{"lat":149,"lon":148},{"facility":152,"status":63,"city":153,"state":154,"zip":155,"country":53,"countryCode":54,"cosmosGeoPoint":156,"geoPoint":160,"contacts":39},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":56,"coordinates":157},[158,159],-74.04347,40.88593,{"lat":159,"lon":158},{"facility":162,"status":49,"city":163,"state":164,"zip":165,"country":53,"countryCode":54,"cosmosGeoPoint":166,"geoPoint":170,"contacts":39},"Roswell Park Comprehensive Cancer Center","Buffalo","New York","14263",{"type":56,"coordinates":167},[168,169],-78.87837,42.88645,{"lat":169,"lon":168},{"facility":172,"status":49,"city":164,"state":164,"zip":173,"country":53,"countryCode":54,"cosmosGeoPoint":174,"geoPoint":178,"contacts":39},"Mt Sinai","10029",{"type":56,"coordinates":175},[176,177],-74.00597,40.71427,{"lat":177,"lon":176},{"facility":180,"status":89,"city":164,"state":164,"zip":181,"country":53,"countryCode":54,"cosmosGeoPoint":182,"geoPoint":184,"contacts":39},"Columbia University Irving Medical Center","10032",{"type":56,"coordinates":183},[176,177],{"lat":177,"lon":176},{"facility":186,"status":49,"city":164,"state":164,"zip":187,"country":53,"countryCode":54,"cosmosGeoPoint":188,"geoPoint":190,"contacts":39},"Memorial Sloan Kettering Cancer Center","10065",{"type":56,"coordinates":189},[176,177],{"lat":177,"lon":176},{"facility":192,"status":49,"city":193,"state":194,"zip":195,"country":53,"countryCode":54,"cosmosGeoPoint":196,"geoPoint":200,"contacts":39},"Duke University Medical Center, Duke Cancer Center","Durham","North Carolina","27710",{"type":56,"coordinates":197},[198,199],-78.89862,35.99403,{"lat":199,"lon":198},{"facility":202,"status":49,"city":203,"state":204,"zip":205,"country":53,"countryCode":54,"cosmosGeoPoint":206,"geoPoint":210,"contacts":39},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":56,"coordinates":207},[208,209],-81.69541,41.4995,{"lat":209,"lon":208},{"facility":212,"status":49,"city":213,"state":214,"zip":215,"country":53,"countryCode":54,"cosmosGeoPoint":216,"geoPoint":220,"contacts":39},"Providence Neurological Specialties West","Portland","Oregon","97225",{"type":56,"coordinates":217},[218,219],-122.67621,45.52345,{"lat":219,"lon":218},{"facility":222,"status":63,"city":223,"state":224,"zip":225,"country":53,"countryCode":54,"cosmosGeoPoint":226,"geoPoint":230,"contacts":39},"Hospital of the University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":56,"coordinates":227},[228,229],-75.16362,39.95238,{"lat":229,"lon":228},{"facility":232,"status":49,"city":233,"state":224,"zip":234,"country":53,"countryCode":54,"cosmosGeoPoint":235,"geoPoint":239,"contacts":39},"UPMC Hilman Cancer Center","Pittsburgh","15232",{"type":56,"coordinates":236},[237,238],-79.99589,40.44062,{"lat":238,"lon":237},{"facility":241,"status":63,"city":242,"state":243,"zip":244,"country":53,"countryCode":54,"cosmosGeoPoint":245,"geoPoint":249,"contacts":39},"University of Tennessee Medical Center","Knoxville","Tennessee","37920",{"type":56,"coordinates":246},[247,248],-83.92074,35.96064,{"lat":248,"lon":247},{"facility":251,"status":252,"city":253,"state":254,"zip":255,"country":53,"countryCode":54,"cosmosGeoPoint":256,"geoPoint":260,"contacts":39},"UT Southwestern Medical Center","ACTIVE_NOT_RECRUITING","Dallas","Texas","75235",{"type":56,"coordinates":257},[258,259],-96.80667,32.78306,{"lat":259,"lon":258},{"facility":262,"status":49,"city":263,"state":254,"zip":264,"country":53,"countryCode":54,"cosmosGeoPoint":265,"geoPoint":269,"contacts":39},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":56,"coordinates":266},[267,268],-95.36327,29.76328,{"lat":268,"lon":267},{"facility":271,"status":49,"city":272,"state":273,"zip":274,"country":53,"countryCode":54,"cosmosGeoPoint":275,"geoPoint":279,"contacts":39},"Huntsman Cancer Institute, University of Utah","Salt Lake City","Utah","84112",{"type":56,"coordinates":276},[277,278],-111.89105,40.76078,{"lat":278,"lon":277},{"facility":281,"status":63,"city":282,"state":283,"zip":284,"country":53,"countryCode":54,"cosmosGeoPoint":285,"geoPoint":289,"contacts":39},"Swedish Cancer Institute","Seattle","Washington","98104",{"type":56,"coordinates":286},[287,288],-122.33207,47.60621,{"lat":288,"lon":287},{"facility":291,"status":49,"city":282,"state":283,"zip":292,"country":53,"countryCode":54,"cosmosGeoPoint":293,"geoPoint":295,"contacts":39},"University of Washington Medical Center","98195",{"type":56,"coordinates":294},[287,288],{"lat":288,"lon":287},{"facility":297,"status":49,"city":298,"state":39,"zip":39,"country":299,"countryCode":39,"cosmosGeoPoint":300,"geoPoint":304,"contacts":39},"Všeobecná fakultní nemocnice v Praze","Prague","Czechia",{"type":56,"coordinates":301},[302,303],14.42076,50.08804,{"lat":303,"lon":302},{"facility":306,"status":49,"city":307,"state":39,"zip":39,"country":308,"countryCode":309,"cosmosGeoPoint":310,"geoPoint":314,"contacts":39},"Institut Bergonie","Bordeaux","France","FR",{"type":56,"coordinates":311},[312,313],-0.58046,44.84124,{"lat":313,"lon":312},{"facility":316,"status":49,"city":317,"state":39,"zip":39,"country":308,"countryCode":309,"cosmosGeoPoint":318,"geoPoint":322,"contacts":39},"Hopital de la Timone","Marseille",{"type":56,"coordinates":319},[320,321],5.38107,43.29695,{"lat":321,"lon":320},{"facility":324,"status":49,"city":325,"state":39,"zip":39,"country":308,"countryCode":309,"cosmosGeoPoint":326,"geoPoint":330,"contacts":39},"Hospital Pitie Salpetriere","Paris",{"type":56,"coordinates":327},[328,329],2.3488,48.85341,{"lat":329,"lon":328},{"facility":332,"status":49,"city":325,"state":39,"zip":39,"country":308,"countryCode":309,"cosmosGeoPoint":333,"geoPoint":335,"contacts":39},"Institut Curie Hospital",{"type":56,"coordinates":334},[328,329],{"lat":329,"lon":328},{"facility":337,"status":49,"city":338,"state":39,"zip":39,"country":339,"countryCode":340,"cosmosGeoPoint":341,"geoPoint":345,"contacts":39},"Hematology Department Soroka UMC \u002F Heanatology Department","Beersheba","Israel","IL",{"type":56,"coordinates":342},[343,344],34.7913,31.25181,{"lat":344,"lon":343},{"facility":347,"status":49,"city":348,"state":39,"zip":39,"country":339,"countryCode":340,"cosmosGeoPoint":349,"geoPoint":353,"contacts":39},"Rambam Medical Center","Haifa",{"type":56,"coordinates":350},[351,352],34.99928,32.81303,{"lat":352,"lon":351},{"facility":355,"status":49,"city":356,"state":39,"zip":39,"country":339,"countryCode":340,"cosmosGeoPoint":357,"geoPoint":361,"contacts":39},"Hadassah Medical Center \u002F Ein-Carem","Jerusalem",{"type":56,"coordinates":358},[359,360],35.21633,31.76904,{"lat":360,"lon":359},{"facility":363,"status":49,"city":364,"state":39,"zip":39,"country":365,"countryCode":366,"cosmosGeoPoint":367,"geoPoint":371,"contacts":39},"Università di Torino Croce e Carle","Cuneo","Italy","IT",{"type":56,"coordinates":368},[369,370],7.54828,44.39071,{"lat":370,"lon":369},{"facility":373,"status":49,"city":374,"state":39,"zip":39,"country":365,"countryCode":366,"cosmosGeoPoint":375,"geoPoint":379,"contacts":39},"SODc Ematologia Azienda Ospedaliera Universitaria Careggi","Florence",{"type":56,"coordinates":376},[377,378],11.24626,43.77925,{"lat":378,"lon":377},{"facility":381,"status":49,"city":382,"state":39,"zip":39,"country":365,"countryCode":366,"cosmosGeoPoint":383,"geoPoint":387,"contacts":39},"IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori","Meldola",{"type":56,"coordinates":384},[385,386],12.0626,44.12775,{"lat":386,"lon":385},{"facility":389,"status":49,"city":390,"state":39,"zip":39,"country":365,"countryCode":366,"cosmosGeoPoint":391,"geoPoint":395,"contacts":39},"IRCCS San Raffaele Scientific Institute","Milan",{"type":56,"coordinates":392},[393,394],12.59836,42.78235,{"lat":394,"lon":393},{"facility":397,"status":49,"city":398,"state":39,"zip":39,"country":399,"countryCode":400,"cosmosGeoPoint":401,"geoPoint":405,"contacts":39},"Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz","Gdansk","Poland","PL",{"type":56,"coordinates":402},[403,404],18.64912,54.35227,{"lat":404,"lon":403},{"facility":407,"status":89,"city":408,"state":39,"zip":39,"country":399,"countryCode":400,"cosmosGeoPoint":409,"geoPoint":413,"contacts":39},"Oddzial Kliniczny Hematologii","Krakow",{"type":56,"coordinates":410},[411,412],19.93658,50.06143,{"lat":412,"lon":411},{"facility":415,"status":49,"city":416,"state":39,"zip":39,"country":399,"countryCode":400,"cosmosGeoPoint":417,"geoPoint":421,"contacts":39},"NarodowyInstytutu Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytutu Badawczy","Warsaw",{"type":56,"coordinates":418},[419,420],21.01178,52.22977,{"lat":420,"lon":419},{"facility":423,"status":49,"city":424,"state":39,"zip":39,"country":425,"countryCode":426,"cosmosGeoPoint":427,"geoPoint":431,"contacts":39},"University Hospital Vall d'Hebron","Barcelona","Spain","ES",{"type":56,"coordinates":428},[429,430],2.15899,41.38879,{"lat":430,"lon":429},{"facility":433,"status":49,"city":434,"state":39,"zip":39,"country":425,"countryCode":426,"cosmosGeoPoint":435,"geoPoint":439,"contacts":39},"MD Anderson Cancer Center Madrid","Madrid",{"type":56,"coordinates":436},[437,438],-3.70256,40.4165,{"lat":438,"lon":437},{"facility":441,"status":49,"city":442,"state":39,"zip":39,"country":425,"countryCode":426,"cosmosGeoPoint":443,"geoPoint":447,"contacts":39},"Hospital Universitario Virgen del Rocio","Seville",{"type":56,"coordinates":444},[445,446],-5.97317,37.38283,{"lat":446,"lon":445},{"type":449,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100310953","phase-1-ca-4948-101-open-label-dose-escalation-and-expansion-trial-of-emavusertib-ca-4948-in-relapsed-or-refractory-primary-central-nervous-system-lymphoma-rr-pcnsl-100310953",false,"NCT03328078","CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R\u002FR PCNSL)","An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma","Inclusion Criteria:\n\n1. Males and females greater than or equal to 18 years of age\n2. Life expectancy of at least 3 months\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n4. Histopathologically confirmed diagnosis of PCNSL (medical record is acceptable). Cerebral biopsies are not required if imaging reveals typical images of PCNSL.\n\n   1. Participants with parenchymal lesions must have unequivocal evidence of disease progression (e.g., presence of at least 1 measurable target lesion \\[≥ 10 millimeters (mm) and ≤ 40 mm in the longest diameter on brain magnetic resonance imaging \\[MRI\\] or head computed tomography \\[CT\\] on imaging within 28 days prior to Cycle 1 Day 1\\]). In cases where the tumor size is smaller but still measurable and located at a critical central nervous system (CNS) location, disabling the participant and\u002For causing symptoms, this participant may be eligible following a discussion with the Sponsor Medical Monitor.\n   2. For participants limited to leptomeningeal involvement, cerebrospinal fluid (CSF) analysis (cytology and\u002For flow cytometry) with or without additional imaging (MRI) of the spine as clinically indicated is required to document abnormal cells within 28 days prior to Cycle 1 Day 1.\n\nExclusion Criteria for Part B and Part C\n\n1. Participants with only intraocular PCNSL without brain lesion or CSF involvement, T-cell lymphoma, systemic presence of lymphoma, or non-CNS lymphoma metastatic to the CNS\n2. Evidence of systemic lymphoma. This must be demonstrated by a positron emission tomography (PET) scan (or CT scan with contrast if applicable) of the chest, abdomen, and pelvis at Screening (testicular ultrasound may be considered to exclude a testicular lymphoma disseminated to the brain).\n3. Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) or prior history of systemic lymphoma, unless the participant has been free of the disease for ≥ 3 years.\n4. Active malignancy other than PCNSL requiring systemic therapy\n5. Previous BTKi treatment (Part C only).\n6. History of Grade ≥ 3 rhabdomyolysis without complete recovery\n7. Requirement for urgent therapy due to uncontrolled tumor mass\u002Fedema effects.\n8. Received external beam radiation therapy to the CNS within 28 days prior to Cycle 1 Day 1.\n9. Received prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1; allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to Cycle 1 Day 1; or had clinically significant graft-versus-host disease (GVHD) requiring ongoing up-titration of immunosuppressive medications prior to Screening (with the exception of a BTKi for Part B only).\n\n   Note: The use of a stable or tapering dose of immunosuppressive therapy post-HSCT and\u002For topical steroids for ongoing skin GVHD is permitted with Sponsor Medical Monitor approval\n10. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 14 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1 (with the exception of ibrutinib or other BTKi for Part B only, which may be continued until the day before Cycle 1 Day 1)\n11. Prior history of hypersensitivity or anaphylaxis to emavusertib, ibrutinib or any of their excipients.","ALL","18 Years",{"count":460,"type":461},152,"ESTIMATED","INTERVENTIONAL",[464,465],"PHASE1","PHASE2","This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R\u002FR) hematologic malignancies.\n\nThis trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete).\n\nPart B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R\u002FR primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles.\n\nPart C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R\u002FR PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R\u002FR PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.",[468,469,470,471],"Relapsed Hematologic Malignancy","Refractory Hematologic Malignancy","Relapsed Primary Central Nervous System Lymphoma","Refractory Primary Central Nervous System Lymphoma",[473,474,475,476,477,478,479,480,481,482,483,484,485,486,36,487,488],"MYD88","IRAK4","NHL","PCNSL","Lymphoma","Neoplasms","Lymphoproliferative Disorders","Lymphatic Diseases","Immunoproliferative Disorders","Immune System Diseases","Lymphoma, Non-Hodgkin","Relapsed\u002Frefractory Central Nervous System (CNS) Lymphoma","Systemic Lymphoma with Concurrent CNS Lymphoma","Systemic Lymphoma with a History of Treated CNS Lymphoma","Bruton tyrosine kinase inhibitor (BTKi)","Primary CNS Lymphoma","2026-04-15",{"date":491,"type":492},"2026-04-16","ACTUAL",{"date":494,"type":492},"2017-12-28",{"date":496,"type":461},"2026-10",{"name":5,"class":6},45]